Avoro Capital Advisors Portfolio
Growth & qualityAvoro Capital Advisors LLC 13F holdings · Q3 2026 vs Q2 2026
Why growth & quality: 26 holdings, 13 effective · top 10 79% · turnover 28% a quarter · earnings yield -1.5% (median 2.9%) · 2 Schedule 13D filings, 0% of the book · 48 quarters of 13Fs
- 13F value
- $9.7bn−13.0% vs $11.1bn in Q2 2026
- Holdings
- 25 3 new · 0 sold out
- Top 10 weight
- 73.6% Largest: UTHR 15.4%
- Bought est.
- $122m New positions and adds
- Sold est.
- $251m Trims and exits
- Quarter
- Q3 2026 Filed
Largest trades since Q2 2026
Estimated dollars: the change in shares times the quarter-end price the filing implies. Exits use last quarter's value.
| Action | Stock | Shares | Est. traded | Weight | Other gurus |
|---|---|---|---|---|---|
| Trimmed | CELCCELCUITY INC | −55.9% | −$151m | 3.2% → 1.2% | 4 |
| New | ABVXABIVAX SA | New | +$48m | 0.0% → 0.5% | 6 |
| New | SCTXSCRIBE THERAPEUTICS INC | New | +$48m | 0.0% → 0.5% | 4 |
| Trimmed | RVMDREVOLUTION MEDICINES INC | −6.6% | −$31m | 3.9% → 4.5% | 8 |
| New | BRVEBRAVEHEART BIO INC | New | +$25m | 0.0% → 0.3% | 4 |
| Trimmed | ARWRARROWHEAD PHARMACEUTICALS INC | −3.1% | −$23m | 8.3% → 7.4% | 4 |
| Trimmed | UTHRUNITED THERAPEUTICS CORP | −0.8% | −$12m | 13.5% → 15.4% | 3 |
| Trimmed | XENEXENON PHARMACEUTICALS INC | −4.8% | −$10m | 3.1% → 2.1% | 4 |
| Trimmed | CYTKCYTOKINETICS INC | −2.0% | −$6.6m | 3.8% → 3.3% | 4 |
| Trimmed | DFTXDEFINIUM THERAPEUTICS INC | −1.9% | −$5.3m | 3.0% → 2.8% | 0 |
| Trimmed | LXEOLEXEO THERAPEUTICS INC | −64.7% | −$3.3m | 0.1% → 0.0% | 4 |
| Trimmed | VERAVERA THERAPEUTICS INC | −1.6% | −$2.9m | 2.2% → 1.9% | 2 |
| Trimmed | SEPNSEPTERNA INC | −2.8% | −$1.5m | 0.4% → 0.5% | 2 |
| Trimmed | OCULOCULAR THERAPEUTIX INC | −1.3% | −$1.2m | 1.1% → 1.0% | 2 |
| Trimmed | FTHFAETH THERAPEUTICS INC | −2.4% | −$1.0m | 0.3% → 0.4% | 4 |
| Trimmed | COAGHEMAB THERAPEUTICS HLDGS INC | −1.7% | −$1.0m | 0.6% → 0.6% | 4 |
| Added | AVTXAVALO THERAPEUTICS INC | +1.9% | +$681k | 0.4% → 0.4% | 5 |
All holdings 25 identified, plus $1.5bn in securities without a listed ticker
Click a column to sort. Values are as reported at quarter-end, not today's prices.
| # | Stock | Shares | ||||
|---|---|---|---|---|---|---|
| 1 | UTHRUNITED THERAPEUTICS CORP | $1.5bn | 2,755,555 | −0.8% | 3 | |
| 2 | KRYSKRYSTAL BIOTECH INC | $961m | 2,888,888 | Unchanged | 2 | |
| 3 | ARGXARGENX SE | $959m | 1,000,000 | Unchanged | 2 | |
| 4 | MDGLMADRIGAL PHARMACEUTICALS INC | $924m | 1,833,333 | Unchanged | 2 | |
| 5 | KYMRKYMERA THERAPEUTICS INC | $836m | 7,474,747 | Unchanged | 3 | |
| 6 | ARWRARROWHEAD PHARMACEUTICALS INC | $720m | 11,000,000 | −3.1% | 4 | |
| 7 | RVMDREVOLUTION MEDICINES INC | $440m | 2,145,000 | −6.6% | 8 | |
| 8 | CYTKCYTOKINETICS INC | $323m | 4,900,000 | −2.0% | 4 | |
| 9 | DFTXDEFINIUM THERAPEUTICS INC | $268m | 7,050,000 | −1.9% | — | |
| 10 | GPCRSTRUCTURE THERAPEUTICS INC | $205m | 6,555,555 | Unchanged | 5 | |
| 11 | XENEXENON PHARMACEUTICALS INC | $205m | 5,500,000 | −4.8% | 4 | |
| 12 | VERAVERA THERAPEUTICS INC | $182m | 5,635,000 | −1.6% | 2 | |
| 13 | CELCCELCUITY INC | $119m | 1,500,000 | −55.9% | 4 | |
| 14 | TSHATAYSHA GENE THERAPIES INC | $116m | 23,888,888 | Unchanged | 5 | |
| 15 | OCULOCULAR THERAPEUTIX INC | $95m | 12,380,300 | −1.3% | 2 | |
| 16 | COAGHEMAB THERAPEUTICS HLDGS INC | $58m | 1,892,372 | −1.7% | 4 | |
| 17 | VRDNVIRIDIAN THERAPEUTICS INC | $51m | 2,500,000 | Unchanged | 6 | |
| 18 | SEPNSEPTERNA INC | $51m | 1,300,000 | −2.8% | 2 | |
| 19 | ABVXABIVAX SA | $48m | 488,000 | New | 6 | |
| 20 | SCTXSCRIBE THERAPEUTICS INC | $48m | 2,598,973 | New | 4 | |
| 21 | FTHFAETH THERAPEUTICS INC | $42m | 1,410,000 | −2.4% | 4 | |
| 22 | AVTXAVALO THERAPEUTICS INC | $36m | 2,377,777 | +1.9% | 5 | |
| 23 | BRVEBRAVEHEART BIO INC | $25m | 1,255,000 | New | 4 | |
| 24 | WHWKWHITEHAWK THERAPEUTICS INC | $11m | 2,849,402 | Unchanged | 1 | |
| 25 | LXEOLEXEO THERAPEUTICS INC | $1.8m | 525,000 | −64.7% | 4 |
Closest portfolios
Overlap is the weight two books have in common: for each shared stock, the smaller of the two weights, summed.
- Baker Bros. Advisors16.7%12 shared · MDGL, KYMR, RVMD, CELC
- Bvf15.7%4 shared · KYMR, RVMD, GPCR, AVTX
- Deerfield Management14.6%8 shared · RVMD, UTHR, VERA, CELC
- Rtw Investments13.8%10 shared · ARGX, CYTK, MDGL, CELC
- Paradigm Biocapital Advisors6.3%4 shared · RVMD, GPCR, VRDN, COAG
- Farallon Capital Management5.1%6 shared · RVMD, AVTX, ABVX, TSHA
- Perceptive Advisors4.0%7 shared · RVMD, CELC, SEPN, SCTX
- Frazier Life Sciences Management3.5%3 shared · KRYS, BRVE, LXEO
- Ra Capital Management3.5%9 shared · TSHA, COAG, SEPN, ABVX
- Novo Holdings2.8%3 shared · XENE, COAG, VRDN
Only here
The largest holdings no other tracked guru owns.
- DFTXDEFINIUM THERAPEUTICS INC2.8%
A 13F is a filing, not a live portfolio. It lists US-listed long stock positions at quarter-end, and it arrives up to 45 days later. Cash, shorts, bonds, options and foreign listings are not in it. Trade sizes here are estimates from the change in share count, restated for stock splits.
Snapshot refreshed